Day: March 28, 2022

Converge Technology Solutions Corp. To Acquire Interdynamix Systems

Written by Customer Service on March 28, 2022. Posted in Mergers And Acquisitions.

Canadian-based Interdynamix will join the Converge portfolio of companies to strengthen the Company’s engineering capabilities and services TORONTO and GATINEAU, Québec, March 28, 2022 (GLOBE NEWSWIRE) — Converge Technology Solutions Corp. (“Converge” or “the Company”) (TSX:CTS) (FSE:0ZB) (OTCQX:CTSDF) a software-enabled IT & Cloud Solutions provider, is pleased to announce it has signed definitive agreements to acquire Interdynamix (IDX), a next-generation systems integrator focused on business, engineering, and innovation. The transaction is expected to close in Q2 2022. Headquartered in Alberta, Canada, Interdynamix was founded in 1995 with the goal of filling a substantial gap in the technology industry for elite engineering resources. Today, IDX is comprised of architects, engineers, sales, and support professionals....

Osisko Metals Announces Signing of an Option Agreement to Acquire Gaspé Copper Mine From Glencore Canada

Written by Customer Service on March 28, 2022. Posted in Mergers And Acquisitions.

MONTREAL, March 28, 2022 (GLOBE NEWSWIRE) — Osisko Metals Incorporated (the “Company” or “Osisko Metals”) (TSX-V: OM; OTCQX: OMZNF; FRANKFURT: 0B51) is pleased to announce that it signed, on March 25 2022, a binding term sheet with Glencore Canada Corporation (“Glencore” and collectively the “Parties”), providing Osisko Metals with an option (the “Option”) to acquire a 100% interest in the past-producing Gaspé Copper Mine (“Gaspé Copper”) located near Murdochville, Québec for an up-front payment of US$25 million, to be paid by Osisko Metals by way of a convertible note issued to Glencore upon the successful closing of the transaction, and a cash payment of US$20 million, payable upon start of commercial production. The Company must also incur drilling costs of C$5 million before June 30, 2022, to test oxidation levels within the...

Form 8.3 – [Clinigen Group plc – 25 03 2022] – (CGWL)

Written by Customer Service on March 28, 2022. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: CANACCORD GENUITY WEALTH LIMITED(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree CLINIGEN GROUP PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e) Date position held/dealing undertaken: For...

Form 8.3 – [CareTech Holdings plc – 25 03 2022] – (CGWL)

Written by Customer Service on March 28, 2022. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree CARETECH HOLDINGS PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e) Date position...

Buybacks of shares in Bilia AB during week 12, 2022

Written by Customer Service on March 28, 2022. Posted in Public Companies.

During the period between March 21-25, 2022 Bilia AB (LEI code 2138002GW5WN1UYZA032) has repurchased in total 235,706 own shares (ISIN SE0009921588 ) as part of the buyback program initiated by the Board of Directors in order to optimize the company’s capital structure. The share buybacks form a part of the buyback program of a maximum of 3,000,000 shares for a total maximum amount of SEK 500 M, which Bilia AB announced on January 19, 2022. The buyback program, which runs between February 9, 2022 – April 7, 2022, is being carried out in accordance with the Market Abuse Regulation (EU) No 596/2014 (”MAR”) and the Commission Delegated Regulation (EU) No 2016/1052 (the ”Safe Harbour Regulation”). The objective of the share buybacks is to optimize the company’s capital structure and the intention is to reduce Bilia’s share capital through...

Auction result of Treasury Bills – RIKV 22 0518 – RIKV 22 0720

Written by Customer Service on March 28, 2022. Posted in Public Companies.

Series RIKV 22 0518 RIKV 22 0720Settlement Date 03/30/2022 03/30/2022Total Amount Allocated (MM) 15,000 6,500All Bids Awarded At (Price / Simple interest) 99.587 / 3.047 98.923 / 3.499Total Number of Bids Received 9 7Total Amount of All Bids Received (MM) 15,600 7,400Total Number of Successful Bids 7 5Number of Bids Allocated in Full 7 5Lowest Price / Highest Simple Interest Allocated 99.587 / 3.047 98.923 / 3.499Highest Price / Lowest Simple Interest Allocated 99.596 / 2.980 98.999 / 3.250Lowest Price / Highest Simple Interest Allocated in Full 99.587 / 3.047 98.923 / 3.499Weighted Average of Successful Bids (Price/Simple Interest) 99.593 / 3.002 98.941 / 3.440Best Bid (Price / Simple Interest) 99.596 / 2.980 98.999 / 3.250Worst Bid (Price / Simple Interest) 99.438 / 4.152 98.892 / 3.601Weighted...

Statera Biopharma, Inc. to Report Fourth Quarter and Full Year 2021 Financial Results on March 31, 2022

Written by Customer Service on March 28, 2022. Posted in Public Companies.

Live Conference Call and Webcast at 5:30 p.m. ET FORT COLLINS, Colo., March 28, 2022 (GLOBE NEWSWIRE) — Statera Biopharma, Inc. (Nasdaq: STAB) (the “Company” or “Statera Biopharma”), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, announced today that the Company will host a conference call and live audio webcast on Thursday, March 31, 2022, at 5:30 p.m. ET, to discuss its corporate and financial results for the fourth quarter and full year ended December 31, 2021. Conference Call & Webcast DetailsDate Thursday, March 31, 2022Time 5:30 p.m. ETLive Audio Webcast https://edge.media-server.com/mmc/p/yffrdzzpTelephone Access: U.S. and Canada 800-937-6813Telephone Access: International 213-660-0853Access Code for All Callers 5398016A...

Enovix Announces BrakeFlow™ Technology

Written by Customer Service on March 28, 2022. Posted in Public Companies.

An Additional Layer of Protection Against Thermal Runaway While Maintaining High Energy DensityEnovix BrakeFlow Illustration BrakeFlow, shown here in green, provides an additional layer of protection against thermal runaway while maintaining high energy densityFREMONT, Calif., March 28, 2022 (GLOBE NEWSWIRE) — Enovix Corporation (“Enovix”) (Nasdaq: ENVX), the leader in the design and manufacture of next generation 3D Silicon™ Lithium-ion batteries, today announced its latest advancement called BrakeFlow™ technology, an intra-cell system that significantly increases tolerance against thermal runaway from internal shorts, without compromising high energy density. “When we founded Enovix in 2007, our approach to improving cell performance was unique from other advanced battery technology companies,” said Harrold Rust, Co-Founder,...

Liberty Gold Reports Year-End 2021 Financial and Operating Results and Announces 110,000 metre Drill Program for 2022

Written by Customer Service on March 28, 2022. Posted in Earnings Releases And Operating Results.

VANCOUVER, British Columbia, March 28, 2022 (GLOBE NEWSWIRE) — Liberty Gold Corp. (TSX:LGD; OTCQX:LGDTF) (“Liberty Gold” or the “Company”), is pleased to announce its financial and operating results for the fiscal year ended December 31, 2021. All amounts are presented in United States dollars unless otherwise stated. The Company is also providing a corporate update on its 2022 work programs at Black Pine and Goldstrike. With the announcement of a 110,000 metre (“m”) full-year 2022 drill program, the Company is once more backing the drill bit and our proven exploration team for further success at our highly prospective oxide gold projects in the Great Basin, USA. Liberty Gold is well funded, with approximately US$34.7 million in cash (as of March 25, 2022), and additional non-dilutive deferred payments from prior property...

GH Research Reports Full Year 2021 Financial Results and Provides Business Updates

Written by Customer Service on March 28, 2022. Posted in Earnings Releases And Operating Results.

DUBLIN, Ireland., March 28, 2022 (GLOBE NEWSWIRE) — GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the full year ended December 31, 2021 and gave updates on its business. Fourth Quarter 2021 Business Highlights In December 2021, we reported the successful outcome of the Phase 2 part of our Phase 1/2 clinical trial of GH001, our proprietary inhalable 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) product candidate, in patients with treatment-resistant depression (TRD) (GH001-TRD-102). The primary endpoint of the Phase 2 part of the trial was met with 7 of 8 patients (87.5%) in remission (Montgomery–Asberg Depression Rating Scale (MADRS) ≤10) at day 7 after dosing (p

Day: March 28, 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice